US Edition
Published • loading... • Updated
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting
KT-621 showed median STAT6 reductions of 94% in skin and 98% in blood after 28 days, with significant clinical improvements and a favorable safety profile in moderate-to-severe atopic dermatitis.
- On Saturday, March 28, 2026, Kymera Therapeutics presented positive Phase 1b results for KT-621 during a late-breaking research session at the American Academy of Dermatology Annual Meeting in Denver, Colorado.
- STAT6 serves as the central driver of Type 2 inflammation, yet patients with moderate-to-severe atopic dermatitis often face access challenges or safety concerns regarding existing systemic treatments like chronic injections.
- In the 22-patient trial, the oral drug demonstrated deep STAT6 degradation with median reductions of 94% in skin and 98% in blood, alongside robust decreases in disease-relevant inflammatory biomarkers.
- Senior Medical Director Mahta Mortezavi reported that the investigational therapy was well tolerated with a favorable safety profile during the oral presentation at the Bellco Theatre.
- Parallel Phase 2b trials are ongoing, with results from the BROADEN2 atopic dermatitis study expected by mid-2027 and the BREADTH asthma trial anticipated by late-2027.
Insights by Ground AI
14 Articles
14 Articles
The Manila Times+2 Reposted by 2 other sources
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting
Investigational ZORYVE® (roflumilast) cream 0.05% was well tolerated with safety findings consistent with prior pediatric experience in the INTEGUMENT programZORYVE cream...
·Manila, Philippines (the)
Read Full Article
Kymera Therapeutics Presents KT-621 BroADen Data in Late-Breaking Research Session at the American Academy of Dermatology (AAD) Annual Meeting - Kymera Therapeutics (NASDAQ:KYMR)
Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621's compelling oral profile Parallel Phase 2b trials, BROADEN2 in atopic dermatitis and BREADTH in asthma, ongoing with data expected by mid-2027 and late-2027, respectively WATERTOWN, Mass., March 28, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral s…
·New York, United States
Read Full ArticleCoverage Details
Total News Sources14
Leaning Left1Leaning Right2Center5Last UpdatedBias Distribution62% Center
Bias Distribution
- 62% of the sources are Center
62% Center
13%
C 62%
R 25%
Factuality
To view factuality data please Upgrade to Premium
